Immunic Inc (IMUX)

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire NEW YORK, June...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting...

Form 8-K - Current report

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR...

Form 8-K - Current report

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire NEW...